Physician profile
Debra A Zack
NPI 1750362901
$642.86
in general payments reported to CMS, 2019-2025
18 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.82 · 2020: $11.40 · 2021: $182 · 2022: $11.71 · 2023: $22.02 · 2024: $100 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $386.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $121.14 | 2025 | Zoryve |
| Amgen INC. | $95.48 | 2021 | |
| Abbvie INC. | $66.42 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $59.83 | 2021-2025 | Rexulti |
| Voco America INC. | $40.36 | 2024 | Voco Retraction Paste, Grandio So, Admira Fusion X-Tra |
| Novo Nordisk INC | $37.47 | 2019 | |
| Corium, LLC | $24.96 | 2025 | Azstarys |
| Indivior INC. | $24.28 | 2021 | |
| Sanofi Pasteur INC. | $22.14 | 2021 | |
| Abbott Laboratories | $22.02 | 2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $20.88 | 2025 | Bexsero, Penmenvy, Shingrix |
| Organon LLC | $19.99 | 2025 | Nexplanon |
| Takeda Pharmaceuticals U.S.A., INC. | $19.84 | 2021 | |
| Gilead Sciences, INC. | $17.09 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $14.50 | 2024 | Breztri |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $13.35 | 2019 | |
| Lilly USA, LLC | $11.71 | 2022 | |
| Welch Allyn | $11.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Zack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.